TXG - CIK 0001770787
10x Genomics, Inc. (TXG) reported revenue of $642.82M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $642.82M | +5.2% |
| FY 2024 | $610.78M | -1.3% |
| FY 2023 | $618.73M | +19.8% |
| FY 2022 | $516.41M | +5.3% |
| FY 2021 | $490.49M | +64.1% |
| FY 2020 | $298.85M | +21.5% |
| FY 2019 | $245.89M | +68.1% |
| FY 2018 | $146.31M | +105.8% |
| FY 2017 |
10x Genomics, Inc. (TXG) reported revenue of $642.82M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2017 and fiscal 2025, 10x Genomics, Inc.'s revenue grew from $71.08M to $642.82M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $71.08M |
| - |